CXCR4 and Miyoshi myopathy: The CXCR4-targeted PET agent [68Ga]PentixaFor has been successfully applied to patients with solid and advanced blood cancers, demonstrating substantially increased radiotracer accumulation in ACC, SCLC, MM, MZL, MCL, or gastric MALT [10, 11, 25, 29, 37, 40].